A Clinical Study on the Hypotensive Effect of Bunazosin(Dentantol(R))

Kang, J C; Park, J C; Cho, J C; Jeong, M H; Park, C H; Gill, G C

Abstract

To evaluate the hypotensive effect and clinical safety of the new alpha-receptor blocking agent bunazosin, 34 hypertensive patients with or without associated were studied, 17 patients with bunazosin only and the other 17 with other drugs and 14 with combined. Twenty nine out 34 patients have finished the 12 weeks trial(15 with single drug and 14 with combined drug regimen). Among 15 single drug patients the systolic blood pressure wer markedly lowered(30mmHg or more)in 6(40%), lowered(29-20mmHg)in 3(20%), the diastolic pressure was markedly lowered(15mmHg or more)in 5(33%), lowered(14-10mmHg) in 4(27%). In 9 patients to whom bunazosin was added because beta-blokers with or without diuretics had not been acceptably effective, systolic blood diastolic blood pressure was markedly lowered in 6 and lowered in another 1. Among 29 patients who have finished the 12 weeka trial systolic blood pressure was markedly lowered in 13(45%), lowered in another6(21%). In 16 patietns among 29 both systolic and diastolic blood pressures were markedly lowered or lowered comprising the effective lowering 55% of cases. Subjective symptoms were much improved in 11, improved in 15, unchanged in 2, slightly worsened in 2 cases, and 4 out of 5 cases who were free of subjective symptoms have stayed free of symptoms. Suggestive side effects were 1 fatique, 1 stuff nose, 1 constipation, and 1 chest pain, all of which were transitory and subsided by decreasing the dose or stopping the drug. There have been no discernible tolerance or side effects in 14 cases who have been treated for 6 months or more up to 16 months. Above results suggested that bunazosin is effective and safe hypotensive agent as a single or combined drug regimen in essential hypertension.